Linden Thomas Advisory Services LLC Has $306,000 Position in Novo Nordisk A/S (NYSE:NVO)

Linden Thomas Advisory Services LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 25.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 3,555 shares of the company’s stock after purchasing an additional 726 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Novo Nordisk A/S were worth $306,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in NVO. International Assets Investment Management LLC lifted its holdings in Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. Mediolanum International Funds Ltd acquired a new stake in Novo Nordisk A/S during the 3rd quarter worth approximately $98,765,000. Wellington Management Group LLP acquired a new stake in Novo Nordisk A/S during the 3rd quarter worth approximately $42,017,000. Sanctuary Advisors LLC acquired a new stake in Novo Nordisk A/S during the 2nd quarter worth approximately $41,646,000. Finally, World Investment Advisors LLC raised its holdings in Novo Nordisk A/S by 2,655.9% in the 3rd quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after acquiring an additional 270,234 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Up 8.4 %

Shares of NVO opened at $87.94 on Monday. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The business’s fifty day moving average is $95.35 and its 200-day moving average is $114.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm has a market cap of $394.65 billion, a price-to-earnings ratio of 28.46, a PEG ratio of 0.90 and a beta of 0.45.

Analysts Set New Price Targets

Several equities analysts have weighed in on NVO shares. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.